A Landscape of Pharmacogenomic Interactions in Cancer
Explore this paper's citation graph
Summary
It is reported how cancer-driven alterations identified in 11,289 tumors from 29 tissues can be mapped onto 1,001 molecularly annotated human cancer cell lines and correlated with sensitivity to 265 drugs.
- Type
- article
- Published
- 2016-07-28
- Cited by
- 1,863
- References
- 42
- Access
- Open access
- OpenAlex
- https://openalex.org/W2461427403
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:15520966
Keywords
Biology, Pharmacogenomics, Cancer, Computational biology, Somatic cell
References
- Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
- The hallmarks of cancer
- Systematic variation in gene expression patterns in human cancer cell lines
- Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium.
- Pan-cancer patterns of somatic copy-number alteration
- Mutational landscape and significance across 12 major cancer types
- The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity
- Cancer Genome Landscapes
- Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
- The cancer genome
- Inactivating CUX1 mutations promote tumorigenesis
- In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities.
- Comprehensive identification of mutational cancer driver genes across 12 tumor types
- Emerging landscape of oncogenic signatures across human cancers
- A community effort to assess and improve drug sensitivity prediction algorithms
- Discovery and saturation analysis of cancer genes across 21 tumor types
- Discovering causal signaling pathways through gene-expression patterns
- The support of human genetic evidence for approved drug indications
- Systematic identification of genomic markers of drug sensitivity in cancer cells
Cited by
- Next-Generation Sequencing of Endobronchial Ultrasound Transbronchial Needle Aspiration Specimens in Lung Cancer.
- Disruption of NSD1 in head and neck cancer promotes favorable chemotherapeutic responses linked to hypomethylation
- Tumor cell resistance against targeted therapeutics: the density of cultured glioma tumor cells enhances Stat3 activity and offers protection against the tyrosine kinase inhibitor canertinib
- Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
- Integrative pharmacogenomics to infer large-scale drug taxonomy
- Synthetic Lethality in Cancer Therapeutics
- A Biomarker Harvest from One Thousand Cancer Cell Lines.
- TANDEM: a two-stage approach to maximize interpretability of drug response models based on multiple molecular data types
- Large variety in a panel of human colon cancer organoids in response to EZH2 inhibition
- Deep Learning and Association Rule Mining for Predicting Drug Response in Cancer. A Personalised Medicine Approach
- Using Pharmacogenomic Databases for Discovering Patient-Target Genes and Small Molecule Candidates to Cancer Therapy
- Precision medicine: from pharmacogenomics to pharmacoproteomics
- Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases
- Big Data Analytics and Cancer
- The challenges of tumor genetic diversity
- TP53 mutations, expression and interaction networks in human cancers
- Looking beyond the cancer cell for effective drug combinations
- A transcriptional signature identifies LKB1 functional status as a novel determinant of MEK sensitivity in lung adenocarcinoma
- Drug response consistency in CCLE and CGP
- COSMIC: somatic cancer genetics at high-resolution
Related papers
- Overcome cancer drug resistance by targeting epigenetic modifications of centrosome
- P53-regulated autophagy and its impact on drug resistance and cell fate
- Cancer drug resistance: a new perspective
- Drug resistance mechanisms of cancer stem-like cells and their therapeutic potential as drug targets
- Targeting DNA repair pathways to overcome cancer drug resistance